We use cookies to improve your experience. By your continued use of this site you accept such use.
Announcements
PrevNext
Novartis

  • Multimedia content

  • Images (3)
    • Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria (1)
    • Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria (2)
    • Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria (3)
  • All (3)
Source: Novartis |

Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria

This Phase 2b study was an open label randomized controlled study conducted in two parts and which enrolled more than 500 patients with acute uncomplicated malaria due to Plasmodium falciparum infection

Novartis (https://www.Novartis.com) and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malaria; In the Phase 2b study conducted in children less than 12 years of age, ganaplacide/lumefantrine met the primary study objective; The positive Phase 2b results for the next…

Novartis

  • Multimedia content

  • Videos (1)
    • No one should die of malaria
  • Images (3)
    • Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment (1)
    • Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment (2)
    • Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment (3)
  • All (4)
Source: Novartis |

Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment

Novartis continues to invest in research and development for next-generation antimalarials to combat the threat of artemisinin resistance

Novartis (www.Novartis.com) has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999; With other innovations, the Novartis artemisinin-based combination therapy (ACT) contributed to reduce malaria deaths by nearly half over the same timeframe [1]; Novartis continues to invest in research and…

Novartis
Source: Novartis |

Novartis renews WHO medicine donation pledge with aim of ending leprosy

Program has already treated over 7 million patients since 2000

Novartis (www.Novartis.com) leprosy medicine donation program with WHO extended to 2025; Program has already treated over 7 million patients since 2000; New evidence from contact tracing and preventive treatment program shows route to accelerate elimination. A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive…

Novartis
Source: Novartis |

GSK and Novartis announce collaboration to support scientific research into genetic diversity in Africa

Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years

Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients; combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years; researchers based at universities, science councils and other public research organizations…

Novartis
Source: Novartis |

Lower-income countries could soon leapfrog high-income countries with AI-enabled health technologies, Novartis Foundation and Microsoft backed report says

The report uses current AI best practices to draw a roadmap that can help all countries advance towards AI maturity in health

Investment in data and AI will be a key tool driving African health system improvements during and after the COVID-19 pandemic; African countries could be the fastest adopters due to lack of legacy systems, but have the most to lose if governments don’t invest now; a third of the adult population…

Novartis
Source: Novartis |

New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines

The African Union through the Africa Medical Supplies Platform (AMSP) has integrated vetted medical suppliers to ensure rapid access to affordable COVID-19 related supplies

The collaboration aims to help alleviate supply and logistical constraints in the African Union member states; Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division will be sold at zero-profit to governments through Africa Medical Supplies Platform (AMSP) to 55 African and 15 Caricom eligible countries; the African…

Novartis
Source: Novartis |

Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

Portfolio will be sold at zero-profit to governments in up to 791 eligible countries during the pandemic and until a vaccine or curative treatment is available

Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptoms; Portfolio will be sold at zero-profit to governments in up to 791 eligible countries during the pandemic and until a vaccine or curative treatment…

Novartis
Source: Novartis |

New Agreements to Expand Access to 20 Lifesaving Cancer Medicines for Countries in Sub-Saharan Africa and Asia

Cancer Access Partnership is expected to result in a 59 percent savings on procured cancer medicines

The American Cancer Society (ACS) and the Clinton Health Access Initiative (CHAI) today announced agreements with pharmaceutical companies Pfizer, Novartis (www.Novartis.com), and Mylan to expand access to 20 lifesaving cancer treatments in 26 countries in sub-Saharan Africa and Asia. Purchasers are expected to save an average of 59 percent for…

Novartis
Source: Novartis |

Novartis expands Africa Sickle Cell Disease program to Uganda and Tanzania

Novartis plans to roll the program out to a total of 10 African countries by 2022

New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care; Program continues progress in Ghana with more than 2000 patients being treated with hydroxyurea in 11 treatment centers across the country; Novartis (www.Novartis.com) plans to roll the program…

Novartis
Source: Novartis |

Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa

A newly formed sub-Saharan Africa unit will deploy innovative approaches to increase patient reach across the full income pyramid

The strategy is aligned with the Novartis Access Principles, which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally; a newly formed sub-Saharan Africa unit will deploy innovative approaches to increase patient reach across the full income pyramid; Novartis (Novartis.com) is building on its…

To Top